BPC-157

BPC-157 is a synthetic peptide consisting of 15 amino acids. FDA’s substance database identifies BPC-157, also known as Bepecin, with the sequence:

GEPPPGKPADDAGLV

The corresponding amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. FDA notes that inclusion of a substance in its identification database does not imply regulatory review or approval.

Its compact and well-defined structure makes BPC-157 of interest for laboratory research involving peptide chemistry and biological signaling.

Research Applications

BPC-157 may be used in controlled experimental settings involving:

• Peptide identity and characterization
• Molecular signaling research
• Cellular experimental models
• Peptide stability studies
• Structure–activity relationships
• Biochemical pathway investigation
• Analytical method development
• Peptide purity assessment
• Molecular interaction studies
• Comparative peptide research

FDA’s 2026 scientific review describes BPC-157 as a 15-amino-acid peptide and evaluated BPC-157 free base and acetate as distinct bulk drug substances.

Product Information

• Product: BPC-157
• Alternative Name: Bepecin
• Classification: Synthetic 15-amino-acid peptide
• Sequence: GEPPPGKPADDAGLV
• Primary Research Area: Cellular and peptide research
• Research Applications: Molecular, biochemical, analytical, and cellular studies
• Supplier: Peptides R US

Why Researchers Study BPC-157

BPC-157 offers researchers a defined 15-residue peptide structure suitable for controlled investigations involving molecular behavior, peptide stability, analytical characterization, and experimental biological pathways.

This makes it a useful addition to research programs examining peptide structure and molecular interactions without making assumptions about therapeutic or human applications.

Research Use Only

BPC-157 supplied by Peptides R US is intended exclusively for laboratory, analytical, and scientific research.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

No dosage, injection, reconstitution-for-human-use, therapeutic, or clinical-use instructions are provided or implied.

FDA currently states that there is limited safety-related information for BPC-157, and that compounded BPC-157 may raise concerns involving immunogenicity, peptide-related impurities, aggregation, and API characterization. FDA therefore says it lacks sufficient information to determine whether such products would cause harm when administered to humans.